Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Dr Mehmood Khan joins Pharmacology as a Visiting Fellow

We are delighted to announce the appointment of Dr Mehmood Khan as a Visiting Fellow in the Department

Mehmood Khan - Visiting FellowDr Khan grew up in Manchester and qualified in medicine from Liverpool University.  He has had a distinguished career as Director of the Diabetes Trials Unit at The Mayo Clinic, former President of the R&D Centre of the Takeda Pharmaceutical Company, and Vice-Chairman and Chief Scientific Officer of PepsiCo. He is currently CEO of The Hevolution Foundation which has a global interest in the science of ageing and improving healthspan.  We warmly welcome Dr Khan to the Department and look forward to his visit in July.

Click here for Dr Khan's full profile

Similar stories

Key cellular channel identified as a brake on lung scarring

Pulmonary fibrosis is a serious and often fatal condition in which lung tissue becomes progressively scarred, stiff, and less able to transfer oxygen into the bloodstream. With limited treatment options and no cure other than lung transplantation, there is an urgent need to understand the biological mechanisms that drive this disease. A new study from the Grimm Group, published in The EMBO Journal, identifies a previously unrecognised protective role for a cellular ion channel called TRPML1 in preventing lung scarring. The research shows that when this channel is absent or non-functional, the lungs develop a fibrosis-like condition marked by excessive accumulation of structural proteins such as collagen and elastin

EMA approval of IntraBio’s Aqneursa marks a major milestone for the Department of Pharmacology, with further Phase 3 success in Ataxia Telangiectasia

Akerman group paper wins inaugural Sejnowski-Hinton Prize

New paper from the Viney group explores mechanisms of spatial disorientation

Behind the photographs: Shared pre-war histories of the British and German Pharmacological Societies

BHF Non-clinical PhD Studentship - apply now